NC-PERCONA
7.12.2021 15:22:12 CET | Business Wire | Press release
Percona , a leader in open source database software and services, today announced Percona Platform to bring together database distributions, support expertise, services, management and automated insights into a single product. Building on the company’s expertise with databases including MySQL, PostgreSQL and MongoDB, the new Percona Platform will simplify how users monitor, manage and optimize their database instances across any infrastructure. In addition, Percona Platform will enable developers and database administrators to run their own private Database-as-a-Service (DBaaS) instances.
This launch will preview the Percona Platform, allowing users to unify the entire database experience from packages and backup to monitoring and management, with general availability in early 2022. Percona brings together distributions of MySQL, PostgreSQL and MongoDB including a range of open source tools for data backup, availability and management. It also includes Percona Monitoring and Management (PMM) for database management, monitoring, and automated insights, making it easier to manage database deployments. The Percona Platform preview will have no up-front commitments or fees to use.
“Three of the biggest challenges database administrators have are standardization, performance and availability. According to our last research report , 59% of developers lost sleep at night due to concerns around downtime and availability. Developers just want things to work, and they want self-service support so they can iterate faster and more independently. Database administrators want help to manage multiple database instances in a consistent approach, so they can deliver a highly available and performant database platform for their development teams as well as their customers. Percona Platform is our response, bringing together everything that developers and DBAs need to implement environments quickly, with less effort and complexity. This launch will help our customers create their applications faster while building upon a strong foundation provided by their database team,” said Donnie Berkholz, Senior Vice President Product at Percona.
Percona Platform will cover all deployment configurations, from internal data center deployments through to public, private and hybrid cloud instances. At general availability, the platform will also cover self-managed and Percona-managed instances, allowing customers the ultimate flexibility to run things the way that best suits their environments, level of confidence and operating models.
The Preview will include:
- Percona Portal - provides access to all Percona services and product expertise in one place
- Percona Account - simplifies user account management for all Percona products and services
- Private DBaaS - enables developers to easily provision and manage databases on a self-service basis across development and testing instances
- Advisors - automated insights to ensure your database is performing at its best
“Percona Platform brings our distributions, expertise and services together in one place. By consolidating all our products this way, developers get unified visibility and control of their entire database environment,” said Ann Schlemmer, President at Percona. “At Percona, we have years of experience helping customers deliver consistent availability, performance and security for their applications and data, and our new Platform approach makes it easier than ever for them to access that expertise within our products.”
The platform is available as a preview at percona.com/platform-preview
Links
- Percona Products - https://www.percona.com/software
- Percona research report on open source database deployments and skills - https://www.percona.com/open-source-data-management-software-survey
- Percona database optimization services - https://www.percona.com/solutions/optimize-database-performance
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway, and the BBC, as well as smaller enterprises looking to maximise application performance while streamlining database efficiencies. For more information, visit www.percona.com .
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom